Cargando…

PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy

BACKGROUND: Protein Tyrosine Phosphatase Receptor-type O (PTPRO) has recently been in the spotlight as a tumor suppressor, whose encoding gene is frequently methylated in cancers. We examined the methylation status of the PTPRO gene promoter in breast cancer and evaluated the correlation between PTP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yi-Teng, Li, Fei-Fei, Ke, Chen, Li, Zhou, Li, Zong-Tai, Zou, Xiao-Fang, Zheng, Xiao-Xuan, Chen, Yu-Ping, Zhang, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852714/ https://www.ncbi.nlm.nih.gov/pubmed/24090193 http://dx.doi.org/10.1186/1479-5876-11-245

Ejemplares similares

PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis
por: Zhang, Wenjie, et al.
Publicado: (2015)

Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients
por: Li, Shao-ying, et al.
Publicado: (2014)

Comprehensively Analyze the Prognosis Significance and Immune Implication of PTPRO in Lung Adenocarcinoma
por: Lin, Zhimin, et al.
Publicado: (2023)

Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma
por: Ming, Fei, et al.
Publicado: (2017)

Study on the Relationship Between PTPRO Methylation in Plasma and Efficacy Neoadjuvant Chemotherapy in Patients with Early Breast Cancer
por: Liu, Xiang-Wei, et al.
Publicado: (2023)

Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance
por: Dong, Hongmei, et al.
Publicado: (2022)

PTPRO represses colorectal cancer tumorigenesis and progression by reprogramming fatty acid metabolism
por: Dai, Weixing, et al.
Publicado: (2022)

PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2
por: Dong, H, et al.
Publicado: (2017)

PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer
por: Hou, Xuben, et al.
Publicado: (2021)

PTPRO-related CD8(+) T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer
por: Dong, Hongmei, et al.
Publicado: (2022)

CRYP-2/cPTPRO is a neurite inhibitory repulsive guidance cue for retinal neurons in vitro
por: Stepanek, Laurie, et al.
Publicado: (2001)

PTPRO predicts patient prognosis and correlates with immune infiltrates in human clear cell renal cell carcinoma
por: Gan, Jinfeng, et al.
Publicado: (2020)

Protein tyrosine phosphatase receptor type O (Ptpro) regulates cerebellar formation during zebrafish development through modulating Fgf signaling
por: Liao, Wei-Hao, et al.
Publicado: (2013)

Black rice-derived anthocyanins inhibit HER-2-positive breast cancer epithelial-mesenchymal transition-mediated metastasis in vitro by suppressing FAK signaling
por: Zhou, Jie, et al.
Publicado: (2017)

MiR-6869-5p Induces M2 Polarization by Regulating PTPRO in Gestational Diabetes Mellitus
por: Wang, Pingping, et al.
Publicado: (2021)

Age-related decline in hippocampal tyrosine phosphatase PTPRO is a mechanistic factor in chemotherapy-related cognitive impairment
por: Yao, Zhimeng, et al.
Publicado: (2023)

Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients
por: He, Weiling, et al.
Publicado: (2013)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
por: Ding, Yi, et al.
Publicado: (2018)

Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia
por: Zhang, Zhanglin, et al.
Publicado: (2019)

The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling
por: Asbagh, Layka Abbasi, et al.
Publicado: (2014)

PTPRO knockdown protects against inflammation in hemorrhage shock-induced lung injury involving the NF-κB signaling pathway
por: Huan, Zhirong, et al.
Publicado: (2022)

Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in HER2‐low breast cancer: A comparison study with HER2‐zero and HER2‐positive disease
por: Lu, Yujie, et al.
Publicado: (2023)

Poorer Search Efficiency in Healthy Young Adults With High Schizotypal Personality Traits
por: Panton, Kirsten R., et al.
Publicado: (2018)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

MiR-6803-5p Promotes Cancer Cell Proliferation and Invasion via PTPRO/NF-κB Axis in Colorectal Cancer
por: Yan, Shushan, et al.
Publicado: (2019)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Patchy echogenicity of the liver in patients with chronic hepatitis B does not indicate poorer elasticity
por: Wu, Size, et al.
Publicado: (2019)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Poorer Integration of Local Orientation Information Occurs in Students With High Schizotypal Personality Traits
por: Panton, Kirsten R., et al.
Publicado: (2018)

Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients
por: Wu, Jiayi, et al.
Publicado: (2017)

National Insurance and the Poorer Hospitals
Publicado: (1914)

Challenges and future of HER2-positive gastric cancer therapy
por: Ma, Chenzhe, et al.
Publicado: (2023)

Shorter telomere length predicts poor antidepressant response and poorer cardiometabolic indices in major depression
por: Rampersaud, Ryan, et al.
Publicado: (2023)

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis
por: Lin, Wu, et al.
Publicado: (2023)

Vitamin D deficiency may predict a poorer outcome of IgA nephropathy
por: Li, Xiao-Hua, et al.
Publicado: (2016)

Efficacy and safety of treatment with or without pertuzumab for HER2-positive breast cancer: A meta-analysis
por: Chen, Xuan, et al.
Publicado: (2023)

Retraction for Motiwala et al., Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer
Publicado: (2022)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
por: Cao, Guo-dong, et al.
Publicado: (2017)

Pain Intensity Is Not Always Associated with Poorer Health Status: Exploring the Moderating Role of Spouse Personality
por: Suso-Ribera, Carlos, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a9jcnv4fbfdd04ckd1jhbk44mv